Figures & data
Figure 1. Antitumor strategies based on γδ T cells. (A) The cell preparation for an “innate allogenic stem cell transplantation” (allo-SCT) from conventional or third party donors may selectively contain or be enriched for γδ T cells to provide anti-cytomegalovirus (CMV) and antitumor protection in the absence of graft versus host disease (GVHD). (B) In a complementary “autologous engineered transplantation,” T cells are isolated from cancer patients, expanded and engineered to express γδ TCRs (optimized by combinatorial-γδTCR-chain exchange) ex vivo. Reprogrammed T cells are subsequently re-infused into the patient, where they specifically recognize and kill tumor cells.
